MedFluid醫流體-Microfluidics專利微流體｜POCT快速診斷｜AST獸醫抗生素用藥檢測｜Molecular Diagnosis核酸檢測

EU Veterinary Antibiotic Regulations Explained: A New Perspective on Companion Animal Treatment in the Era of Antimicrobial Resistance

agent30 — Mon, 01 Sep 2025 06:45:43 +0000

Under the One Health framework, the world is responding to the challenge of Antimicrobial Resistance (AMR) at an unprecedented pace. This issue not only concerns human health but is also closely tied to animal health and environmental protection. As a global leader in regulatory standards, the European Union has introduced the Regulation (EU) 2019/6 on Veterinary Medicinal Products, along with its related provisions, which are beginning to bring profound impacts on the veterinary profession. This article provides an in-depth analysis of these regulations and explores how veterinarians can adopt innovative tools to stay ahead in this era of transformation.

1. EU Regulatory Trends: Precision Medicine and the Role of Companion Animals

Although the market authorization framework for veterinary medicines resembles that of human pharmaceuticals, significant differences exist in industry scale, markets, and target populations. Veterinary medicine must serve a highly diverse set of species, primarily divided into food-producing animals and companion animals. While food animals account for the majority of antibiotic use, the new regulations place increasing emphasis on antimicrobial use in companion animals.
The European Medicines Agency (EMA) categorizes antibiotics into four classes (A, B, C, D) based on their risk to public health and their value in veterinary medicine. These categories apply to all animal species and define clear principles for antimicrobial stewardship:

Category A (Avoid): These antibiotics are generally prohibited for animal use. In exceptional cases—such as therapeutic gaps—they may be used in companion animals, but always under strict conditions and ideally guided by Antimicrobial Susceptibility Testing (AST).
Category B (Restrict): Considered critically important for veterinary medicine, these antibiotics may only be prescribed if no Category C or D alternatives are effective. Their use should likewise be supported by AST results.
Category C (Caution): These antibiotics should only be considered if no suitable Category D option is available.
Category D (Prudence):Recommended as the first-line treatment whenever possible.

This framework demonstrates that antibiotic selection is no longer solely at a veterinarian’s discretion but must follow a stepwise hierarchy of use. Notably, EU member states such as the Netherlands, Belgium, and Denmark now require veterinarians by law to perform AST before prescribing Category B (e.g., fluoroquinolones) or Category A antibiotics (e.g., 3rd/4th generation cephalosporins). This confirms that AST prior to prescription is becoming an inevitable global trend.

2. The Urgency of AMR and the Central Role of AST

The most critical consequence of antibiotic misuse is the emergence of bacterial strains that develop co-resistance or cross-resistance to antibiotics used in human medicine, which can then spread across species. This poses serious risks not only to animal health but also to human health. Studies clearly demonstrate a positive correlation between veterinary antibiotic consumption and antimicrobial resistance in animals, as well as strong associations with resistance in WHO priority human pathogens.
For this reason, the EU emphasizes that prescriptions must be clinically justified. Any antibiotic use must follow clinical examination or health assessment, and whenever possible, pathogen identification and susceptibility testing should precede treatment. This principle applies to all antibiotic categories, not just A or B.
However, traditional AST methods are time-consuming, often requiring several days to produce results. In urgent clinical situations involving companion animals, veterinarians cannot always afford to wait, which can lead to empirical prescribing and subsequently increase the risk of resistance development.

3. Our Solution: Rapid and Accurate AST for Companion Animal Veterinarians

This is precisely the challenge that MedFluid’s NAST system was designed to address. Our diagnostic instrument and consumables for antimicrobial susceptibility testing are tailored for veterinary clinics, delivering accelerated and reliable AST results. This enables veterinarians to:

Comply with regulatory requirements:Our solution provides rapid AST data, ensuring veterinarians remain compliant with increasingly strict regulations, particularly in regions where AST is now mandatory prior to prescribing critical antibiotics.
Enable precision prescribing:Instead of relying solely on experience, symptoms, or medical history, our system provides sample-based susceptibility data to guide every clinical decision—optimizing treatment outcomes and potentially shortening recovery times.
Combat AMR at its roots:By reducing unnecessary or inappropriate use of antibiotics, our platform directly helps slow the emergence and spread of resistant bacterial strains.

The evolution of EU regulations signals a global shift: antibiotic use will be subject to stricter control, while precision medicine will become the new norm. MedFluid’s NAST system stands as the ideal tool for veterinarians navigating this new era. By leveraging technology, we can empower veterinarians to safeguard companion animal health while contributing to the worldwide fight against antimicrobial resistance.

References

Allel, K., et al., 2023. Global antimicrobial-resistance drivers: an ecological country-level study at the human-animal interface. Lancet Planet Health 7, e291-303.
European Medicines Agency (EMA). (2020). Categorisation of antibiotics used in animals promotes responsible use to protect public and animal health. EMA/688114/2020.
European Medicines Agency (EMA). (2022a). Antimicrobial Sales and Use (ASU) data reporting protocol Part 1 Reporting volume of sales. Implementation of the requirements of Regulation (EU) 2019/6 for the collection of data on antimicrobial medicinal products used in animals. EMA/258839/2022.
European Medicines Agency (EMA). (2022b). Sales of veterinary antimicrobial agents in 31 European countries in 2021 – Trends from 2010-2021. Twelfth ESVAC report. Publications Office of the European Union.
Ministry of Health, Welfare and Sport. Animal Health Register, The Netherlands. Regelingdiergeneeskundigen.
Reg. (EU) 2019/6, 2019. Regulation (EU) 2019/6 of the European Parliament and of the Council of 11 December 2018 on veterinary medicinal products and repealing Directive 2001/82/EC. Official Journal of the European Union, L 4, 7.1.2019.
Schmerold, I., Geijlswijk, I. van, & Gehring, R. (2023). European regulations on the use of antibiotics in veterinary medicine. European Journal of Pharmaceutical Sciences, 189, 106473.
World Health Organisation (WHO). (2017). One Health.
World Health Organisation (WHO). (2019). Critically Important Antimicrobials for Human Medicine – 6th revision 2018. Geneva: World Health Organization.

The post EU Veterinary Antibiotic Regulations Explained: A New Perspective on Companion Animal Treatment in the Era of Antimicrobial Resistance first appeared on MedFluid醫流體-Microfluidics專利微流體｜POCT快速診斷｜AST獸醫抗生素用藥檢測｜Molecular Diagnosis核酸檢測.

What Every New Dog Parent Must Understand: A Medical and Ethical Perspective

agent30 — Mon, 11 Aug 2025 06:56:22 +0000

https://medium.com/@medfluid/what-every-new-dog-parent-must-understand-a-medical-and-ethical-perspective-a0ba2de48f02

The post What Every New Dog Parent Must Understand: A Medical and Ethical Perspective first appeared on MedFluid醫流體-Microfluidics專利微流體｜POCT快速診斷｜AST獸醫抗生素用藥檢測｜Molecular Diagnosis核酸檢測.

Urinary Tract Infections (UTIs) in Dogs and Cats: Insights from a Hong Kong Study on Antimicrobial Resistance

admin — Fri, 21 Mar 2025 05:15:58 +0000

Urinary tract infections (UTIs) are common clinical problems in both dogs and cats, often leading to recurrent cases of cystitis and pyelonephritis. In addition to following antimicrobial treatment guidelines¹, regional epidemiological analysis can offer valuable and specific insights to help veterinarians better understand antimicrobial resistance (AMR) trends and make informed treatment decisions.

In 2023, a retrospective study² on UTIs in companion animals was published in Hong Kong, aiming to evaluate the relationship between clinical antimicrobial usage and bacterial resistance patterns from 2018 to 2020. The study analyzed urine culture data from 15,449 canine and feline samples collected over three years. Of these, 5,731 samples (37%) yielded positive bacterial cultures, with dogs accounting for 55.2% and cats for 44.8% of the positive cases.

15449 canine and feline urine samples

2018

2019

2020

Total

No growth

3591

(62%)

2918

(62.4%)

3209

(64.3%)

9718

(63%)

Positive for selection

2196

(38%)

1752

(37.6%)

1783

(35.7%)

5731

(37%)

However, only 311 isolates (11%) out of the 5,731 culture-positive cases were fully susceptible to all tested antimicrobials, while a concerning 56% exhibited multidrug resistance. This highlights the growing complexity in empirical prescribing and the difficulty in selecting effective treatments against diverse bacterial strains.

The study found that the types of pathogens causing UTIs in dogs and cats were relatively consistent. For dogs, the top five bacterial pathogens were Escherichia coli, Proteus spp., Staphylococcus spp., Enterococcus spp., and Klebsiella spp., collectively accounting for approximately 90% of the annual positive samples. For cats, the dominant pathogens included E. coli, Enterococcus spp., Staphylococcus spp., Pseudomonas spp., Proteus spp., and Klebsiella spp., comprising 95% of the positive cases in the same period.

Of particular concern, these common uropathogens demonstrated widespread resistance to first-line antimicrobial agents such as amoxicillin, ampicillin, and trimethoprim-sulfamethoxazole. For example:

E. coli: The most frequently isolated pathogen in feline UTI cases, accounting for 45–49% of positive cat samples annually. It also comprised 34–39% of dog isolates. Resistance to amoxicillin and ampicillin reached 47% in cats and 50% in dogs.
Klebsiella spp.: Exhibited extremely high resistance rates to amoxicillin and ampicillin (>96%) in both species, and moderate resistance (50–60%) to cephalosporins, fluoroquinolones, and penicillins.
Staphylococcus spp.: Showed resistance rates of 78% to amoxicillin and 60% to ampicillin.
Enterococcus spp.: Demonstrated over 95% resistance to trimethoprim-sulfamethoxazole. Moreover, as cephalosporins are ineffective against Enterococci, careful selection of alternative antimicrobials becomes critical to avoid accelerating resistance.

Even more alarming, multidrug resistance—defined as resistance to three or more antimicrobial classes—was observed in 56% of positive cultures, with 68% originating from canine samples. Despite these high resistance rates, the three-year data showed that pathogen distribution and resistance trends remained relatively stable throughout the study period.

In conclusion, this study clearly identifies the predominant pathogens associated with UTIs in dogs and cats in Hong Kong, along with their widespread resistance to first-line antimicrobials—especially the high rate of multidrug resistance. These findings serve as an important alert to clinicians when selecting empirical treatments. While the resistance trends remained stable during the study period, veterinarians should continue to monitor local AMR patterns closely. Whenever possible, bacterial culture and sensitivity testing should be encouraged to guide more accurate and effective antimicrobial choices.

The research team also emphasized that promoting judicious antibiotic use, alongside tools such as diagnostic testing systems, could support veterinarians in making more informed therapeutic decisions—ultimately contributing to the effort to curb the spread of antimicrobial resistance.

References:

J. Scott Weese et. al., International Society for Companion Animal Infectious Diseases (ISCAID) guidelines for the diagnosis and management of bacterial urinary tract infections in dogs and cats, The Veterinary Journal, 2019. https://doi.org/10.1016/j.tvjl.2019.02.008
Olivia S. K. Chan et. al., A Retrospective Study of Antimicrobial Resistant Bacteria Associated with Feline and Canine Urinary Tract Infection in Hong Kong SAR, China—A Case Study on Implication of First-Line Antibiotics Use, Antibiotics, 2022, 11, 1140. https://doi.org/10.3390/antibiotics11091140

At Medfluid, we create simple and reliable tools to help veterinarians find the right treatment for bacterial infections—making care more precise, and helping stop the spread of antimicrobial resistance.
By sharing the latest scientific knowledge, we hope to inspire thoughtful antibiotic use and walk alongside veterinarians as a trusted partner in protecting animal health.

The post Urinary Tract Infections (UTIs) in Dogs and Cats: Insights from a Hong Kong Study on Antimicrobial Resistance first appeared on MedFluid醫流體-Microfluidics專利微流體｜POCT快速診斷｜AST獸醫抗生素用藥檢測｜Molecular Diagnosis核酸檢測.

A wonderful serenity has taken possession3

admin — Fri, 21 Mar 2025 05:15:35 +0000

chemist,scientist hand dropping chemical liquid into test tube, science research and development concept

Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Donec quam felis, ultricies nec, pellentesque eu, pretium quis, sem. Nulla consequat massa quis enim. Donec pede justo, fringilla vel, aliquet nec, vulputate eget, arcu.

In enim justo, rhoncus ut, imperdiet a, venenatis vitae, justo.
Nullam dictum felis eu pede mollis pretium.
Integer tincidunt.

Cras dapibus. Vivamus elementum semper nisi. Aenean vulputate eleifend tellus. Aenean leo ligula, porttitor eu, consequat vitae, eleifend ac, enim. Aliquam lorem ante, dapibus in, viverra quis, feugiat a, tellus. Phasellus viverra nulla ut metus varius laoreet. Quisque rutrum. Aenean imperdiet. Etiam ultricies nisi vel augue. Curabitur ullamcorper ultricies nisi.

Nam eget dui.

Etiam rhoncus. Maecenas tempus, tellus eget condimentum rhoncus, sem quam semper libero, sit amet adipiscing sem neque sed ipsum. Nam quam nunc, blandit vel, luctus pulvinar, hendrerit id, lorem. Maecenas nec odio et ante tincidunt tempus. Donec vitae sapien ut libero venenatis faucibus. Nullam quis ante. Etiam sit amet orci eget eros faucibus tincidunt. Duis leo. Sed fringilla mauris sit amet nibh. Donec sodales sagittis magna. Sed consequat, leo eget bibendum sodales, augue velit cursus nunc, quis gravida magna mi a libero. Fusce vulputate eleifend sapien. Vestibulum purus quam, scelerisque ut, mollis sed, nonummy id, metus. Nullam accumsan lorem in dui. Cras ultricies mi eu turpis hendrerit fringilla. Vestibulum ante ipsum primis in faucibus orci luctus et ultrices posuere cubilia Curae; In ac dui quis mi consectetuer lacinia. Nam pretium turpis et arcu. Duis arcu tortor, suscipit eget, imperdiet nec, imperdiet iaculis, ipsum.

The post A wonderful serenity has taken possession3 first appeared on MedFluid醫流體-Microfluidics專利微流體｜POCT快速診斷｜AST獸醫抗生素用藥檢測｜Molecular Diagnosis核酸檢測.

A wonderful serenity has taken possession2

admin — Fri, 21 Mar 2025 05:13:31 +0000

chemist,scientist hand dropping chemical liquid into test tube, science research and development concept

In enim justo, rhoncus ut, imperdiet a, venenatis vitae, justo.
Nullam dictum felis eu pede mollis pretium.
Integer tincidunt.

Nam eget dui.

The post A wonderful serenity has taken possession2 first appeared on MedFluid醫流體-Microfluidics專利微流體｜POCT快速診斷｜AST獸醫抗生素用藥檢測｜Molecular Diagnosis核酸檢測.

A wonderful serenity has taken possession

agent11 — Fri, 20 Sep 2024 09:12:16 +0000

chemist,scientist hand dropping chemical liquid into test tube, science research and development concept

In enim justo, rhoncus ut, imperdiet a, venenatis vitae, justo.
Nullam dictum felis eu pede mollis pretium.
Integer tincidunt.

Nam eget dui.

The post A wonderful serenity has taken possession first appeared on MedFluid醫流體-Microfluidics專利微流體｜POCT快速診斷｜AST獸醫抗生素用藥檢測｜Molecular Diagnosis核酸檢測.